Tag Archives: Danielle Brill

Analysts Offer Insights on Healthcare Companies: FibroGen (NASDAQ: FGEN) and Phathom Pharmaceuticals (NASDAQ: PHAT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on FibroGen (FGEN – Research Report) and Phathom Pharmaceuticals (PHAT – Research Report). FibroGen (FGEN) Raymond James analyst Danielle Brill maintained a Sell rating on FibroGen

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GW Pharma (NASDAQ: GWPH), Perrigo Company (NYSE: PRGO) and Applied Molecular Transport (NASDAQ: AMTI)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GW Pharma (GWPH – Research Report), Perrigo Company (PRGO – Research Report) and Applied Molecular Transport (AMTI – Research Report). GW Pharma (GWPH) In a

Analysts Offer Insights on Healthcare Companies: GW Pharma (NASDAQ: GWPH), Perrigo Company (NYSE: PRGO) and Applied Molecular Transport (NASDAQ: AMTI)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GW Pharma (GWPH – Research Report), Perrigo Company (PRGO – Research Report) and Applied Molecular Transport (AMTI – Research Report). GW Pharma (GWPH) In a

Analysts Offer Insights on Healthcare Companies: GW Pharma (NASDAQ: GWPH) and Perrigo Company (NYSE: PRGO)

Analysts fell to the sidelines weighing in on GW Pharma (GWPH – Research Report) and Perrigo Company (PRGO – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. GW Pharma (GWPH) Raymond

PTC Therapeutics (PTCT) Gets a Buy Rating from Raymond James

Raymond James analyst Danielle Brill reiterated a Buy rating on PTC Therapeutics (PTCT – Research Report) today. The company’s shares closed last Wednesday at $45.41. According to TipRanks.com, Brill is a 5-star analyst with an average return of 23.0% and

Needham Sticks to Its Buy Rating for Alder Biopharmaceuticals

In a report released today, Danielle Brill from Needham maintained a Buy rating on Alder Biopharmaceuticals (NASDAQ: ALDR), with a price target of $26. The company’s shares opened today at $14.70. Brill said: “Alder had a busy 1Q with new